Abstract
Purpose of investigation:
To determine the effect of imatinib on progression-free survival in patients with epithelial ovarian cancer in second or greater complete clinical remission (CCR).
Methods:
35 patients were enrolled between 10/2002 and 1/2005. Eligible patients received imatinib at 400 mg daily orally.
Results:
One patient withdrew consent, and two patients received protocol therapy in first remission and were excluded. Five patients were removed for possibly related toxicity. No associations were seen between PDGF-R staining and PFS.
Conclusions:
Treatment with imatinib for patients with ovarian cancer in second CCR or greater did not prolong the PFS beyond the historical estimate.
Publication types
-
Clinical Trial, Phase II
-
Research Support, N.I.H., Extramural
MeSH terms
-
Administration, Oral
-
Adult
-
Aged
-
Benzamides
-
Disease-Free Survival
-
Fallopian Tube Neoplasms / drug therapy*
-
Fallopian Tube Neoplasms / mortality
-
Female
-
Humans
-
Imatinib Mesylate
-
Middle Aged
-
Neoplasm Recurrence, Local / prevention & control*
-
Neoplasms, Glandular and Epithelial / drug therapy*
-
Neoplasms, Glandular and Epithelial / mortality
-
Ovarian Neoplasms / drug therapy*
-
Ovarian Neoplasms / mortality
-
Peritoneal Neoplasms / drug therapy*
-
Peritoneal Neoplasms / mortality
-
Piperazines / administration & dosage*
-
Piperazines / adverse effects
-
Protein Kinase Inhibitors / administration & dosage*
-
Protein Kinase Inhibitors / adverse effects
-
Pyrimidines / administration & dosage*
-
Pyrimidines / adverse effects
Substances
-
Benzamides
-
Piperazines
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Imatinib Mesylate